KEI has submitted an amicus brief in support of Respondents in the case of Oil States Energy Services, LLC, v. Greene’s Energy Group, LLC, currently before the Supreme Court. The brief is attached here.
On Friday, 20 October 2017, India delivered the following intervention on compulsory licensing. India briefly recounted the experiences of Brazil, South Africa, and Thailand in using compulsory licensing to secure access to ARVs.
On Friday, 20 October 2017, Brazil delivered the following statement during TRIPS Council discussions on compulsory licensing. Brazil zeroed in a recent compulsory licensing case in Germany involving raltagravir, an antiretroviral.
On 20 October 2017, South Africa delivered the following statement on behalf of Brazil, China, India, and South Africa during the WTO TRIPS Council’s discussions on compulsory licensing. On 31 May 2017, these delegations (along with Fiji) submitted a proposal to the TRIPS Council on “Intellectual Property and the Public Interest” which would serve as an overarching theme for the Council to address issues including access to knowledge and access to medicines. Continue Reading
On October 19, 2017, I ran a query of the USPTO database of granted patents to identify patents granted to the Seattle based Fred Hutchinson Cancer Center.
On October 17, 2017, KEI sent a letter to the NIH regarding the failure of the University of Pennsylvania to disclose federal funding of five patented inventions for CAR T.
Today (October 18, 2017), we received this statement from the University:
“We have reviewed the letter and have confirmed that each of these patents was reported to the government as having NIH funding.
There is an update on this issue, here: /node/2882, noting that the University filed a correction to each of the five patents, reporting federal funding of the inventions.
On October 13, 2017, KEI submitted comments to the WHO regarding the Draft Concept Note towards the WHO’s 13th General Programme of Work. The Draft Concept Note is available here: http://www.who.int/about/draft-concept-note_13th-programme-work.pdf
The text of KEI’s comments follow below, and a PDF is available here.
Friday, 13 October 2017
Dear Dr. Tedros,
The biologic drug, Humira (adalimumab) is currently the best selling drug in the world, with revenues of more than $16 billion in 2016, and $4.7 billion in the 2nd quarter of 2017 ($52 million per day). 
Continue Reading